CPHI 2025: Redefining nutraceuticals with new delivery formats and pharma-grade standards

CPHI 2025: Redefining Nutraceuticals with New Delivery Formats and Pharma-Grade Standards

The distinction between pharmaceuticals and nutraceuticals is narrowing, as showcased at CPHI 2025. The event presented new delivery systems and pharmaceutical-level innovations that are shaping the supplement market.

Industry Convergence and Collaboration

At the trade show, Nutrition Insight explored the intersection of both sectors, speaking with representatives from PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica. These companies discussed how the two fields are increasingly intertwined through shared standards and innovation goals.

Pharma Influence on Supplements

“They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”

Matevž Ambrožič, marketing director at PharmaLinea, explained that the pharmaceutical sector’s influence is pushing supplement makers toward higher quality benchmarks and stronger scientific validation.

Clinical Validation as a Future Standard

“While branded ingredients are increasingly backed by clinical studies, finished-product clinical validation is still rare — and that’s where we focus.”

PharmaLinea emphasizes full clinical substantiation as a step toward pharmaceutical-grade supplements. According to Ambrožič, several of the company’s product lines already meet this level of validation, with more trials underway.

“Our goal is to have our entire portfolio clinically substantiated. That’s our way of adapting to a future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”

Author’s Summary

The CPHI 2025 event revealed how nutraceutical makers are embracing pharmaceutical rigor, shifting toward clinically proven, pharma-grade supplement innovations.

nutritioninsight.com — 2025-11-04